Chief Executive's Statement
PCR CEO, Oliver Kemp, discussed the significant progress we made in 2020, despite the COVID-19 pandemic.
This is a particularly nice impact report to write the introduction for. A few years ago, we set a goal to significantly expand our research from 4 to 23 projects by 2023. At the time it felt incredibly ambitious, but possible if we had the right people, culture, and harnessed the power of our community. Then a pandemic ripped through the whole world, and it all seemed much more challenging.
At the beginning of the pandemic, we agreed that we wouldn’t furlough people, we would keep our research going, fund new research and put in place new initiatives that would make us stronger and more capable of achieving our goals. These initiatives are starting to reap significant rewards. The research we decided to fund in 2020 is underway and we are now funding 15 projects, a 375% increase since 2018. Having reached 15 projects, it now feels like our distant dream of 23 by 2023 is within reach.
We have also changed our approach to put much more focus on targeting key needs for patients within the prostate cancer ecosystem, such as bone metastases. We are adding more value along the way by connecting researchers and trying to ensure that more research is funded all the way to the clinic. To that end, we made an investment in a small biotech, Lucida Medical, that makes prostate scans cheaper, more accessible, and more accurate, and which plans to roll out its technology in late 2022.
It now feels that despite the pandemic, the original long-term goal
is intact due to the tremendous efforts of everyone connected with the organisation.